Aurinia Pharmaceuticals came into this Q3 2026 report with a reputation for eye catching profitability and a stock priced as if that might not last. The latest numbers show quarterly net income of US$31.7 million on revenue of US$83.7 million, yet the share price slipped 3.3% on the first full trading day after the release to US$16.65. That gap between rich reported earnings and a falling ticker is the story. Investors are weighing a very high trailing net margin against forecasts for only modest revenue growth ahead.

Love Aurinia Pharmaceuticals’ eye catching net margin but concerned the share price is treating it as temporary? Take a look at our 30 high quality undervalued stocks.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3…